| Medical and Health Sciences | Lifetime | 124 | US 71 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 16 | US 9 | 100.00 |
| Epidemiology | Lifetime | 3 | US 2 | 99.99 |
| Hepatology | Lifetime | 4 | US 2 | 99.95 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 339 | US 189 | 98.97 |
| Pathology and Forensic Medicine | Lifetime | 727 | US 332 | 96.63 |
| Epidemiology | 2021-2025 | 2 | US 2 | 100.00 |
| Hepatology | 2021-2025 | 12 | US 4 | 99.79 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 130 | US 61 | 98.04 |
| Medical Physiology | 2021-2025 | 706 | US 259 | 88.74 |
| Pathology and Forensic Medicine | 2021-2025 | 321 | US 105 | 89.39 |
| Liver Disease Diagnosis and Treatment | Lifetime | 1 | US 1 | 99.99 |
| Liver Disease and Transplantation | Lifetime | 1 | US 1 | 99.99 |
| Diet, Metabolism, and Disease | Lifetime | 2 | US 2 | 99.97 |
| Liver Diseases and Immunity | Lifetime | 5 | US 4 | 99.91 |
| Alcohol Consumption and Health Effects | Lifetime | 11 | US 8 | 99.74 |
| Endoplasmic Reticulum Stress and Disease | Lifetime | 10 | US 7 | 99.86 |
| Lipid metabolism and disorders | Lifetime | 9 | US 4 | 99.72 |
| Organ Transplantation Techniques and Outcomes | Lifetime | 53 | US 27 | 99.72 |
| Hepatitis C virus research | Lifetime | 65 | US 25 | 99.77 |
| Pancreatitis Pathology and Treatment | Lifetime | 50 | US 23 | 99.60 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 234 | US 73 | 99.11 |
| Hepatitis B Virus Studies | Lifetime | 446 | US 150 | 98.76 |
| Hepatitis Viruses Studies and Epidemiology | Lifetime | 126 | US 45 | 98.41 |
| Diet and metabolism studies | Lifetime | 867 | US 365 | 98.52 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 397 | US 138 | 97.03 |
| Lipid metabolism and biosynthesis | Lifetime | 578 | US 247 | 95.38 |
| Abdominal vascular conditions and treatments | Lifetime | 420 | US 213 | 93.02 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 2 | US 2 | 99.99 |
| Diet, Metabolism, and Disease | 2021-2025 | 2 | US 2 | 99.96 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 1 | US 1 | 99.80 |
| Liver Disease and Transplantation | 2021-2025 | 3 | US 3 | 99.97 |
| Liver Diseases and Immunity | 2021-2025 | 3 | US 3 | 99.92 |
| Pancreatitis Pathology and Treatment | 2021-2025 | 9 | US 4 | 99.59 |
| Alcohol Consumption and Health Effects | 2021-2025 | 19 | US 7 | 98.87 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 77 | US 18 | 98.83 |
| Hepatitis C virus research | 2021-2025 | 57 | US 10 | 98.72 |
| Diet and metabolism studies | 2021-2025 | 235 | US 68 | 97.26 |
| Lipid metabolism and disorders | 2021-2025 | 43 | US 17 | 94.24 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 180 | US 32 | 89.64 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 546 | US 144 | 86.34 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 172 | US 31 | 82.97 |
| Lipid metabolism and biosynthesis | 2021-2025 | 829 | US 157 | 64.36 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 552 | US 163 | 63.92 |
| Fibroblast Growth Factor Research | 2021-2025 | 863 | US 240 | 58.46 |
